Overall and subgroup findings of the aTTom trial: A randomised comparison of continuing adjuvant tamoxifen to 10 years compared to stopping after 5 years in 6953 women with ER positive or ER untested early breast cancer - Rea, D W; Gray, R G; Bowden, S J (Eur J Cancer, 2013)